Henley-in-Arden, 15 April 2013 – Venture capital fund managers Mercia Fund Management (MFM) and Catapult Venture Managers have announced the appointment of Carlton Jones as CEO of nanoTherics, effective immediately. Formerly Global Head of Sales at ThalesNano, Carlton brings over 27 years’ experience in the life sciences sector to his new role, and has been
Open House event seeks to identify innovative start-ups looking for funding Henley-in-Arden, 09 April 2013. Venture capital fund manager Mercia Fund Management (MFM) has announced its first SEIS Fund investments as part of its Mercia Growth Fund 1. With six further SEIS investments rapidly progressing towards investment completion, MFM is pleased to announce its first
Urges start-ups to attend Mercia Fund Management Open House Oxford, 2 April 2013. Oxford-based The Native Antigen Company (NAC) has received new investment from the Mercia Growth Fund 1 and NAC’s existing shareholders. The new investment will accelerate the continued expansion of this now profitable operation which seeks to expand into key markets within the
Henley in Arden, 26 March 2013. Venture capital fund manager Mercia Fund Management has announced its first EIS Fund investments as part of its Mercia Growth Fund 1. Warwick Audio Technologies and nanoTherics will receive investment alongside syndicate investors. Warwick Audio Technologies develops a unique Flat Flexible Loudspeaker technology, which is fundamentally a flat and
What Mercia Fund Management says: “The budget was set in the context for every one job lost in the public sector, 6 are created in the private sector and that a majority of this job growth is within SMEs. The budget was set as a budget for the ‘Aspiration Nation’. We have campaigned hard for
Henley-in-Arden, 15 March 2013. Venture capital fund manager Mercia Fund Management (MFM) has announced that its first Open House event aimed at companies seeking Seed Enterprise Investment Scheme (SEIS) start-up investment or EIS (expansion capital for growing businesses) investment is taking place on 16 April 2013 at Forward House in Henley-in-Arden, Warwickshire. Collectively with Mercia
London, UK, 7 March 2013 – PolyTherics Limited (“PolyTherics”), a provider of solutions for the development of better biopharmaceuticals, announces that it has received an undisclosed milestone payment from Celtic Pharma Holdings (“Celtic”), the international healthcare group, triggered by further progress on their haematology alliance to produce longer-acting versions of blood factor proteins. In 2012
Henley-in-Arden, 6 March 2013. Venture capital fund manager Mercia Fund Management has launched Mercia Growth Fund 2, its second hybrid EIS/SEIS fund. Mercia Growth Fund 2 offers the flexibility to invest either in EIS or SEIS, while enabling investors to maximise tax efficiency. Dr. Mark Payton, Managing Director of Mercia Fund Management commented on the
First-in-Class Anabolic Catabolic Transforming Agent Holds Promise in Treating Cancer Cachexia, Age-Related Sarcopenia OXFORD, UK – March 4, 2013 – PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia. The agent’s unique
Henley in Arden, 18 February 2013. Venture capital fund manager Mercia Fund Management has today announced that Forward Group, an evergreen private equity fund, has become a shareholder. The move strengthens Mercia Fund Management’s position as a provider of venture capital and related services. Terms of the investment were not disclosed. Run by a team